Stanford University
Showing 4,741-4,760 of 36,211 Results
-
Ray Chang
Postdoctoral Scholar, Bioengineering
Current Research and Scholarly Interestsfluid mechanics, ultrafast biophysics, protistology
-
Robert Chang, MD
Professor of Ophthalmology
Current Research and Scholarly InterestsI'm interested in developing a best in class glaucoma registry, utilizing modern algorithm techniques on imaging, text, and biologic data for precision health predictive analytics in glaucoma diagnosis and treatment, validating new medical devices and technologies, especially portable ones, and working on implementation science
-
Spencer Chang
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Spencer Chang is a board-certified Internal Medicine physician who practices at the Stanford Internal Medicine Clinic in Palo Alto. Dr. Chang earned his MD at Duke University School of Medicine where he was part of the Primary Care Leadership Track. He completed his Internal Medicine Residency training at UCLA in the Primary Care Program. Dr. Chang has interests in medical education, improving access to primary care, community health, and Asian Pacific Islander health disparities. He believes in a holistic approach to patient care, addressing the physical, mental, and emotional well-being of his patients and partnering with them to achieve their health goals.
-
Stephanie Tzu-Ying Chang
Assistant Professor of Radiology
BioDr. Stephanie Chang is an Assistant Professor in Radiology at Stanford University School of Medicine and Interim Director of Diagnostic Radiology in the Department of Radiology at VA Palo Alto.
Dr. Chang’s research program aims to utilize state-of-the-art diagnostic technology to non-invasively detect abdominal diseases that predispose or lead to cancer since the most beneficial and cost-effective cancer imaging occurs in the screening/early detection phase.
Currently, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are leading worldwide causes of end-stage liver disease and liver cancer (hepatocellular carcinoma, HCC). To determine the optimal multimodality screening and diagnostic pathway, Dr. Chang leads prospective research studies at VA Palo Alto comparing blood-based and imaging-based diagnostic tests – the Fibrosis-4 (FIB-4) Index, the Enhanced Liver Fibrosis (ELF) test, vibration controlled transient elastography (VCTE), ultrasound point shear wave elastography (US pSWE), and magnetic resonance imaging (MRI) elastography – among high-risk veterans with obesity and/or type 2 diabetes to compare relative performance and costs/benefits.
To improve detection of hepatocellular carcinoma (HCC) among patients with end-stage liver disease (cirrhosis), Dr. Chang also serves as a member of the VA National Radiology Working Group and radiology local site investigator at VA Palo Alto for a multicenter VA research study CSP #2023 PREventing liver cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM STUDY) comparing US and MRI to determine optimal screening strategies for hepatocellular carcinoma.
While MRI has the overall highest sensitivity and specificity for many diseases and contains additional biological/prognostic information not obtainable via other imaging methods, the utility of MRI as a powerful non-invasive screening tool has been hampered by its limitations in access, time, and cost. Dr. Chang is interested in significantly shortening MRI exam times to accelerate MRI throughput, decrease patient discomfort, and reduce costs. To accomplish this goal, Dr. Chang is interested in improving pulse sequences to shorten MRI acquisition times while maintaining or increasing diagnostic quality. In addition, Dr. Chang is interested in novel MRI techniques to improve disease detection and staging. -
Stephen Chang, MD, PhD
Instructor, Biochemistry
Instructor, Medicine - Cardiovascular MedicineBioPrior to a career in medicine, Dr. Chang was an English major and subsequent novelist at night. During the days, he taught literature part-time at Rutgers University, and for extra money, worked in a laboratory in NYC washing test tubes. Inspired by his laboratory mentor, he began volunteering at the hospital next door, and developed a love for interacting with patients. Through this experience, he saw how caring for others could form deep bonds between people - even strangers - and connect us in a way that brings grandeur to ordinary life.
In addition to seeing patients, Dr. Chang is a physician-scientist devoted to advancing the field of cardiovascular medicine. His research has been focused on identifying a new genetic organism that better models human heart disease than the mouse. For this purpose, he has been studying the mouse lemur, the smallest non-human primate, performing cardiovascular phenotyping (vital signs, ECG, echocardiogram) on lemurs both in-bred (in France) and in the wild (in Madagascar) to try to identify mutant cardiac traits that may be heritable - and in the process, characterize the first high-throughput primate model of human cardiac disease. -
Steven D. Chang, MD
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology and Neurological Sciences
Current Research and Scholarly InterestsClinical research includes studies in the treatment of cerebrovascular disorders, such as aneurysms and AVMs, as well as the use of radiosurgery to treat tumors and vascular malformations of the brain and spine.
Dr. Chang is C0-Director of the Cyberknife Radiosurgery Program.
Dr. Chang is also the head of the The Stanford Neuromolecular Innovation Program with the goal of developing new technologies to improve the diagnosis and treatment of patients affected by neurological conditions. -
Tara I. Chang
Stanford University Professor of Nephrology
Current Research and Scholarly InterestsMy research focuses on issues such as blood pressure control, coronary revascularization, and the comparative effectiveness of cardioprotective medications in patients with chronic kidney disease, with the long-term goal of improving cardiovascular outcomes in these high-risk patients.
